These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 29663266)

  • 1. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
    Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
    Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberculosis Screening and Reactivation Among a National Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Antagonists.
    Hou JK; Kramer JR; Richardson P; Sansgiry S; El-Serag HB
    Inflamm Bowel Dis; 2017 Feb; 23(2):254-260. PubMed ID: 27997433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy.
    Vaughn BP; Doherty GA; Gautam S; Moss AC; Cheifetz AS
    Inflamm Bowel Dis; 2012 Jun; 18(6):1057-63. PubMed ID: 21953829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.
    Fidan S; Capkın E; Arıca DA; Durak S; Okatan IE
    Int J Rheum Dis; 2021 Feb; 24(2):254-259. PubMed ID: 33244900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease.
    Lee JM; Wei SC; Lee KM; Ye BD; Mao R; Kim HS; Park SJ; Park SH; Oh EH; Im JP; Jang BI; Kim DB; Takeuchi K
    Gut Liver; 2022 May; 16(3):396-403. PubMed ID: 34593670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.
    Degasperi E; Caprioli F; El Sherif O; Back D; Colombo M; Aghemo A
    Expert Rev Gastroenterol Hepatol; 2016 Dec; 10(12):1373-1383. PubMed ID: 27718758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents.
    Papa A; Felice C; Marzo M; Andrisani G; Armuzzi A; Covino M; Mocci G; Pugliese D; De Vitis I; Gasbarrini A; Rapaccini GL; Guidi L
    J Crohns Colitis; 2013 Mar; 7(2):113-9. PubMed ID: 22464811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
    Chung SJ; Kim JK; Park MC; Park YB; Lee SK
    J Rheumatol; 2009 Nov; 36(11):2416-20. PubMed ID: 19797507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
    Lee YH; Bae SC; Song GG
    Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3).
    Loras C; Gisbert JP; Saro MC; Piqueras M; Sánchez-Montes C; Barrio J; Ordás I; Montserrat A; Ferreiro R; Zabana Y; Chaparro M; Fernández-Bañares F; Esteve M;
    J Crohns Colitis; 2014 Nov; 8(11):1529-38. PubMed ID: 25052345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy.
    Pratt PK; David N; Weber HC; Little FF; Kourkoumpetis T; Patts GJ; Weinberg J; Farraye FA
    Inflamm Bowel Dis; 2018 Jan; 24(2):380-386. PubMed ID: 29361083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.
    López-Serrano P; Pérez-Calle JL; Sánchez-Tembleque MD
    World J Gastroenterol; 2013 Mar; 19(9):1342-8. PubMed ID: 23538480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study.
    Papalopoulos I; Fanouriakis A; Kougkas N; Flouri I; Sourvinos G; Bertsias G; Repa A; Avgoustidis N; Sidiropoulos P
    Clin Exp Rheumatol; 2018; 36(1):102-109. PubMed ID: 28850029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.
    Hunt CM; Beste LA; Lowy E; Suzuki A; Moylan CA; Tillmann HL; Ioannou GN; Lim JK; Kelley MJ; Provenzale D
    World J Gastroenterol; 2016 May; 22(19):4732-40. PubMed ID: 27217704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
    Lee YH; Bae SC; Song GG
    Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases.
    Belle A; Baumann C; Bigard MA; Zallot C; Gizard E; Guéant JL; Bronowicki JP; Peyrin-Biroulet L
    Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):877-81. PubMed ID: 26121376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases.
    Kim YJ; Bae SC; Sung YK; Kim TH; Jun JB; Yoo DH; Kim TY; Sohn JH; Lee HS
    J Rheumatol; 2010 Feb; 37(2):346-50. PubMed ID: 20008922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
    Nakamura J; Nagashima T; Nagatani K; Yoshio T; Iwamoto M; Minota S
    Int J Rheum Dis; 2016 May; 19(5):470-5. PubMed ID: 24698305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus reactivation during anti-cancer chemotherapy in patients with past hepatitis B virus infection.
    Kim E; Yune S; Ha JM; Lee WJ; Hwang JW; Paik YH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Hepatogastroenterology; 2014 Sep; 61(134):1704-11. PubMed ID: 25436366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.